Kyorin Pharmaceutical has signed a joint sales promotion agreement with Santen Pharmaceutical for Allegion\u00ae Eyelid Cream in Japan, planning to commence promotion to non-ophthalmic medical institutions from August 2026. The initiative aims to expand business and improve patient QOL.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4569","jir_company_name":"Kyorin Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-07-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4569-20260713-01.pdf","jir_short_summary":"Kyorin Pharmaceutical has signed a joint sales promotion agreement with Santen Pharmaceutical for Allegion\u00ae Eyelid Cream in Japan, planning to commence promotion to non-ophthalmic medical institutions from August 2026. The initiative aims to expand business and improve patient QOL.","jir_summary":"### Overview of the Contract Signing\nKyorin Pharmaceutical has entered into a joint sales promotion agreement with Santen Pharmaceutical to strengthen the sales of Allegion\u00ae Eyelid Cream. Santen will handle manufacturing, sales, and promotion within the ophthalmology field, while Kyorin will expand to non-ophthalmic medical institutions. The drug, launched in May 2024, aims to promote widespread adoption, contributing to improved QOL for patients.\n\n### Future Outlook and Impact\nThis contract will provide a new treatment option for allergic conjunctivitis and facilitate business expansion while enhancing patients' quality of life. Specific impacts on the consolidated performance for the fiscal year ending March 2027 have not been disclosed, but increased sales activities are expected to support long-term growth.","jir_financial_highlights":"Unknown: Unknown (Unknown)","jir_category":"","jir_hashtags":"#KyorinPharmaceutical, #BusinessStrategy, #JapaneseStocks","jir_key_figures":"Unknown\nUnknown\nUnknown","jir_meta_title":"\u3010Kyorin Pharmaceutical\u3011 Allegion\u00ae Cream Sales Promotion Agreement \uff5c July 2026","jir_meta_description":"Kyorin Pharmaceutical has entered into a joint sales promotion agreement with Santen Pharmaceutical for Allegion\u00ae Eyelid Cream, starting sales in August 2026. The initiative aims for business expansion and improved patient QOL.","jir_og_title":"\u3010Kyorin Pharmaceutical\u3011 Allegion\u00ae Cream Sales Promotion Agreement \uff5c July 2026","jir_og_description":"Kyorin Pharmaceutical has signed a joint sales promotion agreement with Santen Pharmaceutical, beginning sales in August 2026. The effort focuses on business growth and enhancing patient QOL.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16660,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"business_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-79917","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n